Bullish & Foolish
Full NTHI fundamentals All 466 on the Survival Watch

NTHINEONC TECHNOLOGIES HOLDINGS, INC.

Is Neonc Technologies Holdings struggling financially?

Yes, by its own account. Neonc Technologies Holdings told the SEC on 15 May 2026, in Form 10-Q, that there is substantial doubt about its ability to continue as a going concern.

Going concern disclosed May 2026

15/100

Critical

Cries for help

Nothing in the filings we have read reads as a plea for help.

Signs of a way out

  • Regulatory win

    The Company’s lead products include NEO100 and NEO212. NEO100 is in clinical trials treating glioblastoma and has Orphan Drug and Fast Track designation from the United States Food and Drug Administration (“FDA”).

    Form 10-Q, filed 15 May 2026. Read it on SEC.gov

Sector
Biotech/Pharma
Market cap
$121.3M
Source filing
10-Q 15 May 2026
Balance sheet
30 Jun 2026

Cash runway

  • 1month

    If the burn speeds up

    Empty by Jul 2026

  • 2months

    If it eases off

    Empty by Aug 2026

Both rows are the same reported burn flexed 15% either way, and neither assumes the company raises a cent.

Out of cashTwo years or more

The runway math

Cash and short-term investments

$2.0M

÷

Cash burned over the last 12 months

$20.9M

What Neonc Technologies Holdings told the SEC

…additional financing will be available when needed, whether it will be available on favorable terms, or if it will be available at all. These factors raise substantial doubt regarding the Company’s ability to continue as a going concern one year from the issuance date of this Form 10-Q. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

NEONC TECHNOLOGIES HOLDINGS, INC., Form 10-Q, filed 15 May 2026.

Read the filing on SEC.gov

What this means

  • Not a bankruptcy filing, and not a prediction.
  • It is the company’s own statement, agreed with its auditor, that the doubt is material enough to disclose.
  • The runway is arithmetic on two reported numbers, not a forecast. Companies carry this language for years, raise money and keep going.

What else the numbers show

  • 29.0% share-count increase The company issued stock. Each share now owns 22.5% less of the business than a year ago, before any change in the price.

Other Biotech/Pharma companies that filed the doubt